Accordingly, pSTAT3 expression on peripheral-blood CD4+ T cells and Tregs from melanoma patients was correlated with the clinical benefit from adjuvant treatment with PD-1 inhibitor [59]. This evidence concerns the gene CD4 and melanoma.